2022. All rights reserved by Arcensus GmbH

2022. All rights reserved by Arcensus GmbH

"Digital transformation is impacting all areas of healthcare and society, not least because there is a growing need for digital products with the COVID 19 pandemic. However, the need for digital transformation in diagnostics and especially in genomic medicine goes deeper. The availability of wearable smart sensors, artificial intelligence and whole genome sequencing (WGS) data is changing the research and implementation landscape in personalised/precision medicine (PPM).

Digital transformation will massively accelerate PPM on many fronts, e.g. deep real-time phenotyping with patient-specific outcomes, high-throughput association studies between WGS and high-granularity phenotypic variation, digital clinical trials, and more."

The talk offers an analysis of these systems science frontiers with a view to future applications at the intersection of digital health and personalised medicine.


The Arcensus Partner Program

Partnering with Arcensus can open the door for your business to take advantage of the personal and preventive healthcare market based on genetics with a TAM of $47.6BN (2025E) and a short- and medium-term SOM of $1.2BN (first 10 markets).

Enquire now

Prof. Dr. Arndt Rolfs is a multi-entrepreneur in biotech, founder, and former CEO of several innovative biotech companies, including Nasdaq-listed company CENTOGENE.

He has scaled CENTOGENE from a small genetic diagnostics start-up to a global organization focused on advancing the understanding of the pathophysiology of rare hereditary diseases.


Currently, Prof. Rolfs is on another exciting quest to save human lives by disrupting the medical & genetic diagnostics market with our new biotech start-up Arcensus GmbH.

OUR CEO AND FOUNDER

Prof. Dr. Arndt Rolfs

The Arcensus Partner
Program

Partnering with Arcensus can open the door for your business to take advantage of the personal and preventive healthcare market based on genetics with a TAM of $47.6BN (2025E) and a short- and medium-term SOM of $1.2BN (first 10 markets).

Book a 1 on 1 meeting with Prof. Dr. Arndt Rolfs, CEO Arcensus GmbH and former CEO Centogene/Germany at the Arab Health global healthcare event and discuss partnership opportunities with Arcensus.

Enquire now

OUR CEO AND FOUNDER

Prof. Dr. Arndt Rolfs

Prof. Dr. Arndt Rolfs is a multi-entrepreneur in biotech, founder, and former CEO of several innovative biotech companies, including Nasdaq-listed company CENTOGENE. 

He has scaled CENTOGENE from a small genetic diagnostics start-up to a global organization focused on advancing the understanding of the pathophysiology of rare hereditary diseases.

Currently, Prof. Rolfs is on another exciting quest to save human lives by disrupting the medical & genetic diagnostics market with our new biotech start-up Arcensus GmbH.

Book a 1 on 1 meeting with Prof. Dr. Arndt Rolfs at the Arab Health global healthcare event and discuss partnership opportunities with Arcensus.

Enquire now

ARCENSUS

Empowering People

Arcensus is a digital healthcare and diagnostics company that empowers people to take control of their health. We believe that good health should not be a matter of luck, but rather a matter of informed and timely action. Therefore, we provide a secure, trusted, and comprehensive medical service based on Whole Genome Sequencing (WGS).

TECHNOLOGY

Whole Genome Sequencing

Arcensus uses Whole Genome Sequencing to analyse the complete genetic information in human DNA and identify the predispositions as well as reasons for unclear symptoms with the help of cutting-edge technology like artificial intelligence.

Globally, 500M+ people are affected by rare genetic disorders, and unfortunately these diseases are typically diagnosed after 6 to 8 years.

Arcensus has developed comprehensive genetic tests, that help to diagnose the diseases earlier, suggest better treatment options and help individuals take preventive measures to live a healthier and longer life.

Interested in partnering up and changing the future of genetic testing together?

Our Products

Our solutions are developed by world’s leading scientists specialized in human genetics with the primary focus on clinical relevance. Our services are redefining personal health from the ground up by combining digital health and DNA sequencing.

myLifeHeart™

myLifeHeart™ analyses more than 450 genes related to hereditary heart diseases and at-risk-conditions in order to find certainty and start timely treatment.

myLifeCancer™

myLifeCancer™ analyses more than 1000 cancer relevant genes and helps to identify cancer early and to give you the opportunity to maximise health outcomes.

Based on your unclear symptoms and positive family history, myLifeDNA™ analyses your genetic information in order to provide answers and make a genetic diagnosis. myLifeDNA™ includes the analysis of all cardiac and cancer related genes.

myLifeGenome™

If you cannot attend the Arab Health event but want to know more about our partner program, please get in contact via the contact form.

Enquire now

By submitting this form you agree to the privacy policy.

Book a 1 on 1 meeting with Prof. Dr. Arndt Rolfs, CEO Arcensus GmbH and former CEO Centogene/Germany at the Arab Health global healthcare event and discuss partnership opportunities with Arcensus.

Attend Prof. Rolfs’ Speech at Arab Health 2022 to learn about

Digital Changes in Personalized Medicine Based on Genomic Technologies

Book a 1 on 1 meeting with Prof. Dr. Arndt Rolfs at the Arab Health global healthcare event and discuss partnership opportunities with Arcensus.

Enquire now

ARCENSUS

Empowering People

Arcensus is a digital healthcare and diagnostics company that empowers people to take control of their health
We believe that good health should not be a matter of luck, but rather a matter of informed and timely action. Therefore, we provide a secure, trusted, and comprehensive medical service based on Whole Genome Sequencing (WGS).

TECHNOLOGY

Whole Genome Sequencing

Arcensus uses Whole Genome Sequencing to analyse the complete genetic information in human DNA and identify the predispositions as well as reasons for unclear symptoms with the help of cutting-edge technology like artificial intelligence.

Globally, 500M+ people are affected by rare genetic disorders, and unfortunately these diseases are typically diagnosed after 6 to 8 years.

Arcensus has developed comprehensive genetic tests, that help to diagnose the diseases earlier, suggest better treatment options and help individuals take preventive measures to live a healthier and longer life.

Our Products

Our solutions are developed by world’s leading scientists specialized in human genetics with the primary focus on clinical relevance. Our services are redefining personal health from the ground up by combining digital health and DNA sequencing.

myLifeHeart™

myLifeHeart™ analyses more than 450 genes related to hereditary heart diseases and at-risk-conditions in order to find certainty and start timely treatment.

myLifeCancer™

myLifeCancer™ analyses more than 1000 cancer relevant genes and helps to identify cancer early and to give you the opportunity to maximise health outcomes.

myLifeGenome™

Based on your unclear symptoms and positive family history, myLifeDNA™ analyses your genetic information in order to provide answers and make a genetic diagnosis. myLifeDNA™ includes the analysis of all cardiac and cancer related genes.

If you cannot attend the Arab Health event but want to know more about our partner program, please get in contact via the contact form.

Enquire now

Attend Prof. Rolfs’ Speech at Arab Health 2022 to learn about

Digital Changes in Personalized Medicine Based on Genomic Technologies

DateJanuary 27, 2022 | Time11:30 AM | Venue: Sheikh Saeed Hall, 
Transformation Zone, Booth S2.D70, Dubai World Trade Center

"Digital transformation is impacting all areas of healthcare and society, not least because there is a growing need for digital products with the COVID 19 pandemic. However, the need for digital transformation in diagnostics and especially in genomic medicine goes deeper. The availability of wearable smart sensors, artificial intelligence and whole genome sequencing (WGS) data is changing the research and implementation landscape in personalised/precision medicine (PPM).

Digital transformation will massively accelerate PPM on many fronts, e.g. deep real-time phenotyping with patient-specific outcomes, high-throughput association studies between WGS and high-granularity phenotypic variation, digital clinical trials, and more."

The talk offers an analysis of these systems science frontiers with a view to future applications at the intersection of digital health and personalised medicine.

DateJanuary 27, 2022 | Time11:30 AM | Venue: Sheikh Saeed Hall,
Transformation Zone, Booth S2.D70 ,
Dubai World Trade Center